ヒト免疫不全ウイルス（HIV）-1治療法の世界市場分析：薬の種類別（ヌクレオシドアナログ逆転写酵素阻害剤（NRTI）、非NRTI、侵入･融合、プロテアーゼ、インテグラーゼ阻害剤、補助受容体拮抗薬）、セグメント予測、2014-2025...市場調査レポートについてご紹介

Table of Content

Chapter 1 Methodology & Scope
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sources
Chapter 2 Executive Summary and Market Snapshot
2.1 Market Snapshot
Chapter 3 HIV-1 Therapeutics Market Variables, Trends& Scope
3.1 Market segmentation & scope
3.2 Market size and growth prospects
3.2.1 Market Driver Analysis
3.2.2 Market Restraint Analysis
3. Penetration & growth prospect mapping
3.4 HIV-1 Therapeutics Market – SWOT Analysis, By Factor (political & legal, economic and technological)
3.5 Industry Analysis – Porter’s
Chapter 4 HIV-1 TherapeuticsMarket Drug Class Estimates & Trend Analysis
4.1 HIV-1 Therapeutics market: Drug Class movement analysis
4.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
4.2.1 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) market estimates and forecasts, by drug class, 2014 – 2025 USD Million
4.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
4.3.1 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)market estimates and forecasts, by drug class, 2014 – 2025 USD Million
4.4 Entry and Fusion Inhibitors
4.4.1 Entry and fusion Inhibitors market estimates and forecasts, by drug class, 2014 – 2025 USD Million
4.5 Protease Inhibitors (PIs)
4.5.1 Protease Inhibitors (PIs) market estimates and forecasts, by drug class, 2014 – 2025 USD Million
4.6 Integrase Inhibitors
4.6.1 Integrase inhibitors market estimates and forecasts, by drug class, 2014 – 2025 USD Million
4.7 Coreceptor Antagonists
4.7.1 Coreceptor antagonists market estimates and forecasts, by drug class, 2014 – 2025 USD Million
Chapter 5 HIV-1 Therapeutics Market Regional Estimates & Trend Analysis
5.1 HIV-1 Therapeutics market share by region, 2014& 2025
5.2 North America
5.2.1 North America market estimates and forecasts, by drug class, 2014 – 2025 USD Million
5.2.1.1 U.S.
5.2.1.2 Canada
5.3 Europe
5.3.1 Europe market estimates and forecasts, by drug class, 2014 – 2025 USD Million
5.3.1.1 UK
5.3.1.2 Germany
5.4 Asia Pacific
5.4.1 Asia Pacific market estimates and forecasts, by drug class, 2014 – 2025 USD Million
5.4.1.1 Japan
5.4.1.2 China
5.4.1.3 India
5.5 Latin America
5.5.1 Latin America market estimates and forecasts, by drug class, 2014 – 2025 USD Million
5.5.1.1 Mexico
5.5.1.2 Brazil
5.6 MEA
5.6.1 MEA market estimates and forecasts, by drug class, 2014 – 2025 USD Million
5.6.1.1 South Africa
Chapter 6 Competitive Landscape
6.1 Strategy framework
6.2 Company Profiles
6.2.1 AbbVie, Inc.
6.2.1.1 Company Overview
6.2.1.2 Financial Performance
6.2.1.3 Product Benchmarking
6.2.1.4 Strategic Initiatives
6.2.2 Boehringer Ingelheim GmbH
6.2.2.1 Company Overview
6.2.2.2 Financial Performance
6.2.2.3 Product Benchmarking
6.2.2.4 Strategic Initiatives
6.2.3 Bristol-Myers Squibb Company
6.2.3.1 Company Overview
6.2.3.2 Financial Performance
6.2.3.3 Product Benchmarking
6.2.3.4 Strategic Initiatives
6.2.4 Cipla, Inc.
6.2.4.1 Company Overview
6.2.4.2 Financial Performance
6.2.4.3 Product Benchmarking
6.2.4.4 Strategic Initiatives
6.2.5 Genentech, Inc.
6.2.5.1 Company Overview
6.2.5.2 Financial Performance
6.2.5.3 Product Benchmarking
6.2.5.4 Strategic Initiatives
6.2.6 Gilead Sciences, Inc.
6.2.6.1 Company Overview
6.2.6.2 Financial Performance
6.2.6.3 Product Benchmarking
6.2.6.4 Strategic Initiatives
6.2.7 Merck & Co., Inc.
6.2.7.1 Company Overview
6.2.7.2 Financial Performance
6.2.7.3 Product Benchmarking
6.2.7.4 Strategic Initiatives
6.2.8 ViiV Healthcare
6.2.8.1 Company Overview
6.2.8.2 Financial Performance
6.2.8.3 Product Benchmarking
6.2.8.4 Strategic Initiatives